GlobeNewswire Inc | Sep 30, 2021 07:05AM EDT

September 30, 2021

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming investor and scientific conferences:

-- Chardans 5th Annual Genetic Medicines Conference, October 4 - 5, 2021Members of uniQures management team, including Matt Kapusta, chief executive officer, will participate in virtual one-on-one investor meetings the morning of Tuesday, October 5th.A fireside chat with Matt Kapusta will take place the same day from 8:00 to 8:30 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website. -- Alliance for Regenerative Medicine: Cell & Gene Meeting on the Mesa, October 12 - 14, 2021Joshua Leeman, Ph.D., VP, Search & Evaluation, Business Development, will be making a corporate presentation on Wednesday, October 13th at 12:15 p.m. PDT. Dr. Leeman will also be participating in a panel entitled, Delivering the Innovation of Gene Therapy to Patients Through Strategic Collaborations Workshop on Thursday, October 14th starting at 7:15 a.m. PDT. -- European Society of Gene and Cell Therapy (ESGCT), October 19 22. 2021uniQure will present multiple preclinical data presentations at the meeting. Specific details to follow when the meeting abstracts are released. -- Jefferies Gene Therapy/Editing Summit, October 27 - 28, 2021Members of uniQures management team including Ricardo Dolmetsch, Ph.D., president of Research & Development, will participate virtually in one-on-one investor meetings throughout the day on Thursday, October 28th. A fireside chat with Matt Kapusta will take place the same day from 12:00 to 12:30 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.

About uniQure uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with severe genetic diseases of the central nervous system (CNS) and liver, including clinical programs in hemophilia B and Huntington's disease and preclinical candidates in Fabry disease, spinocerebellar ataxia Type 3, temporal lobe epilepsy, Alzheimers, Parkinsons, and ALS. www.uniQure.com

uniQure Contacts: FOR INVESTORS: FOR MEDIA: Maria E. Cantor Chiara Russo Tom MaloneDirect: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com